The effectiveness and value of tabelecleucel for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease

被引：0
|
作者：
Mckenna, Avery [1 ]
Lin, Grace A. [1 ]
Lee, Woojung [1 ]
Raymond, Finn [1 ]
Richardson, Marina [1 ]
Agboola, Foluso [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02108 USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2025年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：429 / 434
页数：6
相关论文
共 50 条
  • [21] Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV+) Leiomyosarcomas (LMS)
    Jimenez-Kurlander, Lauren S.
    Behr, Gerald
    Bunin, Nancy J.
    Doubrovina, Ekaterina
    Dinavahi, Rajani
    Gamelin, Laurence
    Ghobadi, Armin
    Mascarenhas, Leo
    Nikiforow, Sarah
    O'Reilly, Richard J.
    Price, Anita
    Shulkin, Barry
    Srinivasan, Ashok
    Suser, Stephanie
    Wahlstrom, Justin
    Xing, Baodong
    Prockop, Susan
    BLOOD, 2022, 140 : 7524 - 7526
  • [22] Immune-mediated Neuropathy with Epstein-Barr virus-positive T-cell Lymphoproliferative Disease
    Hattori, Takaaki
    Arai, Ayako
    Yokota, Takanori
    Imadome, Ken-Ichi
    Tomimitsu, Hiroyuki
    Miura, Osamu
    Mizusawa, Hidehiro
    INTERNAL MEDICINE, 2015, 54 (01) : 69 - 73
  • [23] Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-positive lymphomas: are we there yet?
    Jones, Kimberley
    Gandhi, Maher K.
    LEUKEMIA & LYMPHOMA, 2009, 50 (05) : 684 - 686
  • [24] Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder
    Roychowdhury, S
    Baiocchi, RA
    Vourganti, S
    Bhatt, D
    Blaser, BW
    Freud, AG
    Chou, J
    Chen, CS
    Xiao, JJ
    Parthun, M
    Chan, KK
    Eisenbeis, CF
    Ferketich, AK
    Eisenbeis, CSCA
    Grever, MR
    Chen, CS
    Caligiuri, RA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1447 - 1457
  • [25] Successful treatment of Epstein-Barr virus (EBV) posttransplant lymphoproliferative disease (PTLD) with low dose chemotherapy
    Gross, TG
    Baker, KS
    Bierman, PI
    Sammut, P
    Greiner, TC
    Hinrichs, SH
    Langnas, AN
    BLOOD, 1996, 88 (10) : 346 - 346
  • [26] Cordycepin enhances Epstein-Barr virus lytic infection and Epstein-Barr virus-positive tumor treatment efficacy by doxorubicin
    Du, Yinping
    Yu, Jieshi
    Du, Li
    Tang, Jun
    Feng, Wen-Hai
    CANCER LETTERS, 2016, 376 (02) : 240 - 248
  • [27] Allograft liver biopsy in patients with Epstein-Barr virus - Associated posttransplant lymphoproliferative disease
    Randhawa, P
    Blakolmer, K
    Kashyap, R
    Raikow, R
    Nalesnik, M
    Demetris, AJ
    Jain, A
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) : 324 - 330
  • [28] Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity?
    Leblond, V
    Davi, F
    Charlotte, F
    Dorent, R
    Bitker, MO
    Sutton, L
    Gandjbakhch, I
    Binet, JL
    Raphael, M
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2052 - 2059
  • [29] Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes
    Lindsay, Julian
    Othman, Jad
    Heldman, Madeleine R.
    Slavin, Monica A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2021, 34 (06) : 635 - 645
  • [30] Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation
    Allen, U. D.
    Preiksaitis, J. K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 107 - 120
12345